Co-founder, Protagonist Therapeutics
Appears in 1 story
Developed the Vectrix peptide platform underlying ICOTYDE
For two decades, treating moderate-to-severe psoriasis required needles — self-injected drugs or clinic infusions many patients refused or abandoned. On March 18, 2026, the FDA approved ICOTYDE, a once-daily pill that blocks the IL-23 receptor like injectable biologics. In trials of roughly 2,500 patients, about 70 percent achieved clear or almost clear skin at 16 weeks, with side effects within 1.1 percentage points of placebo.
Updated May 30
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
